Hideto Oshikawa

Learn More
OBJECTIVE To assess the effectiveness, drug survival and safety of tocilizumab compared with TNF-α inhibitors in clinical practice. METHODS Patients in the Cohort of Arthritis Biologic Users at Kameda Institute (CABUKI) registry who were on biologics during July 2003 to October 2010 were included. Remission rates at 6 months, Kaplan-Meier drug survival(More)
the June issue of Arthritis Research & Th erapy [1]. Th e study compared the Disease Activity Score in 28 joints calculated by using C-reactive protein (DAS28-CRP) versus American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission in terms of residual pain. Th e authors stated that DAS28-CRP remission criteria allowed for(More)
  • 1